BIOLIGHT Life Sciences Investments Ltd.

Obecure Is Granted Methods and Composition Patents Covering Adjunctive Use of Betahistine
Obecure Executes Licensing and Clinical Supply Agreement With Farmaceutici-Formenti SPA
IOptima Receives European Patent Approval for its IOPtiMateTM Laser System
IOPtima Launches OT-135
Dr. Floyd Taub Joins Zetiq Scientific Advisory Board
Zetiq Team Publishes Article in Journal of Histotechnology
IOPtima Receives CE Approval of its IOPtiMate(TM) Laser System for Treatment of Glaucoma
Obecure Achieves Successful Results in its Proof of Concept Study on Histalean and Olanzapine
Obecure Completes Patient Enrollment for Phase IIb Trial with HistaleanTM in Obesity
Zetiq Reports Success in Clinical Trial Aimed to Identify and Diagnose Cervical Cancer
IOPtima Glaucoma Treatment Shows Sustained Success
Obecure Recruits First Patient in Phase II Obesity Study in Pre-Menopausal Women
IOPtima Successfully Completes Initial Clinical Study For Glaucoma Using Novel Laser-Based Therapy
Obecure Signs Strategic Agreement with Farmaceutici-Formenti of the Grunenthal Group for Manufacturi
Top Analyst Calls Bio-Light Stock Undervalued
IOPtima Completes Pre-Clinical Trials for Novel Laser-Based Therapy for Glaucoma
The Whites of their Eyes: IOptima
IOPtima Completes Development of Novel Laser-Based Therapy for Glaucoma
Zetiq Completes Cancer Diagnosis Kit
Obecure Completes Treatment of Patients in Phase II Obesity Trial
Obecure Initiates Phase II Study to Examine Effect of OBE101 on Plasma Lipids in Patients Treated Wi
Obecure Completes Patient Enrollment for Phase II Obesity Trial
Obecure Initiates Phase II Weight Gain Prevention Study for Patients Taking Zyprexa
Bio-Light to allocate 5 million shares to Menorah-Mivtachim
Obecure to Investigate Effect of Flagship Drug on Cholesterol
Obecure Recruits First Patient in Phase II Obesity Study
Eli Lilly to support OBEcure Phase II trials
Rodman and Renshaw Investments Selected to Lead Obecure Private Placement in US
NIH Will Conduct Clinical Trials on Flagship Product OBE101
Chief Scientist Approves Grant to Allergica
Dr. Joshua Degani Named CEO of IOPtima
Obecure receives FDA approval for PHASE II Clinical Trials
ObeCure Receives Permission from Canada for Clinical Trial
ObeCure To Enter the Appetite Stimulant Market
Dr. Yaffa Beck Appointed CEO of ObeCure
Allergica signs development accord with Dow Pharmaceuticals
Bio-Light Public Offering Raises NIS 30.6 Million
Bio-Light Institutional Placement Oversubscribed
Allergica Patent Request Approved
Allergica signs contract with US institute for development of asthma drug
ObeCure Metabolite Twice As Effective
Zetiq: Diagnostic Kits To Be Ready Within 3 Months
A new Israeli solution for a weighty problem
Obecure May Proceed to Phase 2 Clinical Trials
Obecure Term Sheet to Raise Up to $1.5M
Zetiq Submits 7 New Patent Requests
Optotech Patent Approved in U.S.
OBEcure Reports New Findings
Dr. Yaffa Beck Joins Allergica as Chairman
Dr. Nir Barak To Lecture at Texas Conference Hebrew ver.
Allergica To Team With Tel Aviv University.

Eli Lilly to support OBEcure Phase II trials

By Michal Yoshai-Horovits

Globes, Jan. 22, 2007

Eli Lilly & Co. will support Phase II clinical trials by Bio-Light Life Sciences Investments, Ltd, portfolio company OBEcure Ltd.

The trial of OBEcure’s OBE101 drug will be conducted in Canada on 78 schizophrenia patients taking Eli Lilly’s anti-psychotic drug Zyprexa.

Eli Lilly’s support for the trial could total a few hundred thousand dollars. OBEcure will allow Eli Lilly to review the results of the trial before publication.

The trial will examine the effectiveness of OBE101, compared with a placebo in preventing weight gain as a side effect of taking Zyprexa.

Back to News/Information

© 2006 BIO-LIGHT Life Sciences Investments Ltd. Design by MWF	Bio-Light Ltd. - Israeli Life Sciences Investments Ltd. Paz Tower (9th floor) 5-7 Shoham St. 52521 Ramat-Gan , Israel Tel.: +972 (0)3 7534100 Fax: +972 (0)3 7515134